Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Chief Technology Officer

Chief Legal Officer

Chief Executive Officer

Chief Financial Officer

Chief Development Officer

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-24	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-24	Premium	sold	Premium	Premium	Premium	Chief Technology Officer
2024-04-24	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-04-17	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-17	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-04-17	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-17	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-17	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-04-09	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-09	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-04-09	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	-
2024-04-02	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	-
2024-04-02	Premium	acquired	Premium	Premium	Premium	-
2024-04-02	Premium	acquired	Premium	Premium	Premium	Chief Technology Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	-
2024-04-02	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-04-02	Premium	acquired	Premium	Premium	Premium	-
2024-02-22	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-02-22	Premium	sold	Premium	Premium	Premium	Chief Financial Officer

IMVT - Immunovant Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for IMVT